Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer
| Autor: | Jagmeet P. Singh, Insija Ilyas Selene, Farah Wani, Shakeel Jamal, Asim Kichloo, Michael Albosta, Asma Taj, Michael Aljadah |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
atezolizumab medicine.medical_specialty Lung Neoplasms Epidemiology medicine.medical_treatment Case Report Antineoplastic Agents Antibodies Monoclonal Humanized Small-cell carcinoma 03 medical and health sciences 0302 clinical medicine Atezolizumab Prednisone Internal medicine Bell's palsy medicine Bell Palsy lcsh:Pathology Humans Safety Risk Reliability and Quality Adverse effect 030304 developmental biology Aged 0303 health sciences lcsh:R5-920 Palsy business.industry Immunotherapy Bell’s palsy medicine.disease Small Cell Lung Carcinoma 030220 oncology & carcinogenesis immune-related adverse events Female Complication business lcsh:Medicine (General) Safety Research medicine.drug lcsh:RB1-214 |
| Zdroj: | Journal of Investigative Medicine High Impact Case Reports, Vol 8 (2020) Journal of Investigative Medicine High Impact Case Reports |
| ISSN: | 2324-7096 |
| Popis: | Immune checkpoint inhibitors are rapidly becoming popular therapeutic options for patients suffering from a number of malignancies. Atezolizumab is a programmed cell death ligand-1 inhibitor, and binding to this ligand decreases the ability of tumor cells to evade the immune system, resulting in self-tolerance. While inhibition of these molecules leads to increased T-cell destruction of tumor cells, it also may lead to autoimmune destruction of healthy cells. Neurotoxicity is a rare complication of immune checkpoint inhibitor therapy, and facial palsy as a complication of atezolizumab therapy has only been reported in one additional study. We present the case of a 68-year-old female with a history of small cell carcinoma of the lung presenting with sudden-onset facial palsy and numbness of the distal extremities in the setting of receiving atezolizumab immunotherapy. Our patient was managed with temporary cessation of her immunotherapy, oral prednisone, and supportive measures. Within 4 weeks, the patient had complete resolution of her facial palsy and was able to resume immunotherapy without further complication. Clinicians should be aware of this rare adverse effect in order to enact early management including temporary cessation of therapy to prevent morbidity in patients undergoing immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|